Zymes is engaged in developing a novel, water-soluble, readily applicable patented formulation of nano-micellar complex of CoQ10 and pro-drug form of vitamin E (WS-CoQ10), licensed from the National Research Council Canada.
CoQ10’s efficacy in the brain may increase through Zymes’ formulation and allow its use at lower dosages.
The formulation offers a near-complete protection for dopamine nerve cells in the pre-clinical models of PD as a result of its prophylactic application.
Zymes CEO Vincent Morano said the recognition of the significant potential of Zymes’ technology by the Michael Fox Foundation will strengthen the alliance between the organizations.
The project, ‘Evaluation of the Neuroprotectivity Ability of Zymes’ Water-soluble CoQ10 (WS-CoQ10) in Animal Models of PD (Parkinson’s disease): Preclinical Validation and Dose Optimizations for Clinical Study,’ will be conducted by Zymes in collaboration with the National Research Council of Canada (NRC) and the University of Windsor (Ontario, Canada.